Floatz Rating
B59/100
Confidence
Indicative
Sponsor
University of Virginia
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06428682CT.gov Role of TXA in Patients Undergoing Breast Free Flap Reconstruction | — | Recruiting | — | — | — |
NCT07434453CT.gov "Topical Tranexamic Acid With Flap Fixation: A Novel Approach to Minimize Post-operative Drainage and Surgical Site Infection in Patients Undergoing Modified Radical Mastectomy" | — | Completed | — | — | — |
NCT05807074CT.gov Impact of Topical Tranexamic Acid in Breast Reconstruction | — | Terminated | — | — | — |
NCT04918589CT.gov Tranexamic Acid for Alloplastic Breast Reconstruction | — | Unknown | — | — | — |
NCT05554211CT.gov Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage | — | Withdrawn | — | — | — |
NCT03738527CT.gov SEroma Reduction pOst MAstectomy "SEROMA Study" | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tranexamic Acid (this asset) | University of Virginia | Approved | B · 59 |
| Darolutamide | Vandana Abramson | P2 | BBB |
| Pertuzumab | SWOG Cancer Research Network | P4 | BB |
| Palbociclib | Hoffmann-La Roche | P4 | BB |
| Trastuzumab Duocarmazine | Byondis B.V. | P3 | BB |
| Goserelin | TerSera Therapeutics LLC | P4 | BB |
| Ribociclib | National Cancer Institute (NCI) | P4 | BB |
| Oxaliplatin | Beijing Biostar Pharmaceuticals Co., Ltd. | P4 | BB |
| Eribulin Monomethanesulfonate | Henan Cancer Hospital | P4 | BB |
+42 more in the Breast Cancer cohort
Other indications for Tranexamic Acid
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Intracerebral Hemorrhage | — | P4 | BB · 71 |
| Post-Operative Wound Seroma, Non-Human Animal | — | P4 | BB · 69 |
| Brain Injury | — | P3 | BB · 68 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tranexamic Acid in Breast Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tranexamic-acid-breast-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →